載入中
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
前收盤價
US$7.16
+US$0.19 · +2.73%
盤中時間採用ET。市場資料可能有所延遲。
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
日內區間
目前US$7.16
52週區間
目前US$7.16
盤中時間採用ET。市場資料可能有所延遲。
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
日內區間
目前US$7.16
52週區間
目前US$7.16
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 營收 | 2405萬 USD | — | — | — |
| 銷貨成本 | 349.6萬 USD | 315.2萬 USD | — | 25萬 USD |
| 毛利 | 2055.4萬 USD | −315.2萬 USD | — | −25萬 USD |
| 研究與開發 | 3.86億 USD | 2.66億 USD | 1.38億 USD | 1.01億 USD |
| 銷售、一般及管理費用 | 9185.6萬 USD | 3520萬 USD | 2049.8萬 USD | 1254.6萬 USD |
| 營業費用 | 4.48億 USD | 2.98億 USD | 1.58億 USD | 1.14億 USD |
| 利息收入 | 1418萬 USD | 1202萬 USD | 336.8萬 USD | 199.2萬 USD |
| 折舊和攤銷 | 349.6萬 USD | 315.2萬 USD | 128.4萬 USD | 25萬 USD |
| 營業利益 | −4.27億 USD | −3.01億 USD | −1.58億 USD | −1.14億 USD |
| 淨利 | −2.43億 USD | −2.94億 USD | −1.55億 USD | −1.12億 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6866.81萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF2160.84萬0.02%954億 USD0.05%US$235+0.80%
iShares Russell 2000 ETFIWM1442.06萬0.02%787.4億 USD0.19%US$278.94+0.49%
Vanguard Russell 2000 ETFVTWO989.81萬0.05%180億 USD0.06%US$112.66+0.50%
State Street SPDR S&P Pharmaceuticals ETFXPH667.03萬1.45%4.62億 USD0.35%US$64.65+1.60%
iShares Biotechnology ETFIBB520.42萬0.05%108.2億 USD0.44%US$206.49+3.00%
iShares Russell 2000 Growth ETFIWO511.45萬0.04%139.17億 USD0.24%US$356.78+0.94%
Vanguard Health Care ETFVHT390.39萬0.02%220億 USD0.09%US$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOState Street SPDR S&P Pharmaceuticals ETFXPHiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
